andrew ritter  ritter pharmaceuticals inc  zoominfocom ritter pharmaceuticals lactose intolerance experts pharma biotech experience  ritter pharmaceuticals ritter pharmaceuticals  therapeutic treatments for gastrointestinal diseases careerscontact connect with us home about us history leadership overview leadership team medical advisory board board of directors lactose intolerance overview health consequences standard of care market opportunity patient resources microbiome modulation investors overview events  presentations corporate governance sec filings  stock info investor faqs contact us news press releases  news blog contact us contact us careers lactagen rpg product pipeline  print this page leadership team ritter pharma has recruited and assembled an outstanding team of talented and experienced individuals with extensive big pharma  biotech experience michael d step chief executive officer prior to joining ritter mr step was the senior vice president of corporate development for santarus inc now a wholly owned subsidiary of salix pharmaceuticals inc mr step served in this role for nine years up until the  sale of santarus to salix mr step was responsible for leading all licensing and ma activities at santarus and was a member of its executive team prior to his tenure at santarus mr step held various commercial and business development roles at amylin pharmaceuticals for  years culminating in the role of vice president of corporate development and was responsible for leading amylin’s license of byetta to eli lilly before joining amylin mr step was sr director of business development at dura pharmaceuticals and served in licensing management and sales roles at hoffmannla roche and syntex labs mr step has an mba degree in marketing and finance from the usc marshall school of business and an undergraduate degree from vanderbilt university andrew j ritter cofounder  president mr ritter cofounded ritter pharmaceuticals inc upon his own personal affliction with lactose intolerance and spearheaded a global team of crossfunctional clinical manufacturing and regulatory experts to design and develop its first novel therapeutic called rpg this product has been successfully tested in a phase a trial and has the potential to become the first fdaapproved drug for the treatment of lactose intolerance the company was originally launched out of ritter naturals sciences a directtoconsumer healthcare marketing company founded by mr ritter in  which developed and commercialized digestive healthcare products lactagen® health essentials™ and better digestion™ mr ritter holds six patents and over fifteen additional international patents are pending in addition he has copublished articles in the following journals nutrition journal gastroenterology and food technology he has also given presentations at major healthcare and medical conferences such as digestive disease week among others since  mr ritter has also acted as managing partner of stonehenge partners a private investment fund which provides working capital and executive leadership to a variety of businesses and industries including real estate technology biotechnology entertainment and service businesses in addition he is a guest lecturer of entrepreneurship at various graduate and undergraduate academic institutions throughout los angeles including university of southern california marshall school of business university of california at los angeles anderson school of business and pepperdine university graziadio school of business and management mr ritter has been an active leader in his community including being appointed as a los angeles city commissioner to the commission for children youth and their families from  the youngest appointed commissioner in los angeles history mr ritter holds a bachelor of arts degree in political science and a minor in business from the university of southern california and was a member of the  pac champion baseball team in addition mr ritter received his mba from the wharton school university of pennsylvania ira e ritter cofounder  chief strategic officer mr ritter has extensive experience creating building and managing diverse business enterprises his success has been his ability to take ideas and grow major businesses he currently serves as chairman of ritter pharmaceuticals in addition he provides corporate management strategic planning and financial consulting for a wide range of market segments in the health and beauty sector mr ritter was president and vicechairman of quality king inc the nation’s largest wholesale distributor for health care products with  billion in annual revenues ranked the th largest privately held company forbes top  list simultaneously he worked as president and chairman of rockwood a business he developed that produced private label hba products for major national retailers including gnc and kmart in the entertainment sector he served as chairman of ontv a division of oak industries nyse company where he managed the television division initiating exclusive broadcasts of los angeles chicago and new york professional baseball basketball and hockey games during  he produced the first televised home shopping program and directed development of the largest “payperview” channel system for its time in the personal services market mr ritter grew a peopletopeople business elite personal search and lifemates personal matchmaking service in the us and canada in the finance field mr ritter served on the board of directors for the martin lawrence art galleries nyse company during his  years as a publisher he produced monthly national consumer magazines including playgirl and released books that included it’s ok to say no childrens series and patti regan davis’ homefront mr ritter also has a long history of public service that includes appointments by three governors to several state of california commissions including eight years served as commissioner on the california prison industry authority in  mr ritter was honored with the city of hope’s man of the year award ellen mochizuki vice president finance ms mochizuki has over  years of experience in financial accounting prior to joining ritter pharmaceuticals inc ms mochizuki consulted with various biopharmaceutical clients with respect to their initial public offerings and related financial statements as well as assisting with a stock merger for a publicly traded midsize banking client from  to  ms mochizuki served as director of accounting benefits for northrop grumman corporation ngc where she was responsible for the overall accounting and accounting operations of its benefit assets of over  billion including the filing of over twenty external financial statements annually from  to  ms mochizuki was a consultant for ngc from  to  ms mochizuki was senior vice president at indymacbank where she oversaw human resources operations ms mochizuki started her career as an auditor with pricewaterousecoopers llp in addition ms mochizuki is an adjunct faculty at pasadena city college teaching accounting present ms mochizuki is licensed in the state of california as a certified public accountant though is currently on inactive status leadership board of directors leadership team medical advisory board overview home    about us    investors    therapies    platform    leadership    lactose intolerance    news     contact us    privacy policy    terms  conditions    site map  copyright  ritter pharmaceuticals all rights reserved featuring recent posts wordpress widget development by yd andrew j ritter  holliston ma  intelius sign in we found andrew j ritter in holliston ma andrew j ritter intelius found that andrew j ritter is a male between  and  years old from holliston ma we have connected them to  addresses  phones and  relatives or associates also known as andy j ritter get report now age andrew j ritter is in his s andrew has lived in holliston ma boston ma natick ma andrews relatives kathleen ritter lawrence ritter barbara ritter michael ritter andrew j ritter zodiac signgemini gendermale professional status suffolk university get report now want to know more about andrew get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about andrew or use our people search engine to find others get background check on andrew j ritter get a criminal check on andrew j ritter get a public record report on andrew j ritter get a people search report on andrew j ritter andrew j ritters contact information known cities lived in find out where andrew j ritter has lived as well as andrew j ritters phone numbers and email addresses andrew j ritter has lived in  states massachusetts address for andrew j ritter  d d holliston ma has lived in holliston ma boston ma get full address report phone numbers associated with andrew j ritter    holliston ma    holliston ma get full phone report email addresses associated with andrew j ritter aacom aredu get email report andrew j ritters professional information information regarding andrew j ritters professional history find out previous places andrew j ritter has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act andrew j ritter has worked at  place company suffolk university andrew j ritters experience title company suffolk university job details suffolk university located on bostons historic beacon hill with campuses in madrid and dakar senegal africa is a comprehensive global institution distinguished by its teaching and the intellectual contributions of its faculty suffolk offers a wide range of undergraduate and graduate programs in more than  areas of study its mission is to provide quality education at a reasonable cost for students of all ages and backgrounds with strong emphasis on diversity additional professional information on andrew j ritter see andrew j ritters linkedin profile andrew j ritters social network and potential email matches find out potential social network profiles and potential email usernamed for andrew j ritter andrew j ritters known social networks and potential email matches find all of andrew j ritters social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches andrew ritter username matches andrewritter ritterandrew andrewritter ritterandrew andrewritter ritterandrew andrewritter ritterandrew aritter popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches a ritter intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here andrew j ritter executive profile  biography  bloomberg july    am et pharmaceuticals company overview of ritter pharmaceuticals inc snapshotpeople  overviewboard memberscommittees executive profile andrew j ritter cofounder president corporate secretary  director ritter pharmaceuticals incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background mr andrew j ritter cofounded ritter pharmaceuticals inc in march  and has been the president of ritter pharmaceuticals inc since  mr ritter mr ritter served as chief executive officer of ritter pharmaceuticals inc until october  he has been actively studying the field of lactose intolerance for over  years since  he has also acted as managing partner of stonehenge partners a private investment fund which provides working capital and  executive leadership to a variety of businesses and industries those industries include real estate tech biotech entertainment and service businesses he serves as secretary at ritter pharmaceuticals inc he has been a director at ritter pharmaceuticals inc since  he is a guest lecturer of entrepreneurship at various graduate and undergraduate schools throughout los angeles including marshall school of business university of southern california anderson school of business university of california of los angeles and pepperdine university graziadio school of business and management los angeles mayor richard riordan appointed mr ritter to serve as a los angeles city commissioner from  to  the youngest appointed commissioner in los angeles history he was a member of the  pac champion baseball team mr ritter holds a bachelor degree in political science and a minor in business from the university of southern california he graduated from the stanford graduate school of business’ executive education on influence and negotiation strategiesread full background corporate headquarters  century park eastlos angeles california united statesphone fax  board members memberships presentcofounder president corporate secretary  directorritter pharmaceuticals inc education bachelors degree university of southern californiamba university of pennsylvania  the wharton schoolunknownother education stanford graduate school of business other affiliations university of southern californiauniversity of pennsylvania  the wharton schoolstanford graduate school of business annual compensation salarybonustotal annual compensation stocks options exercisable optionsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact ritter pharmaceuticals inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close ritter pharmaceuticals leading lactose intolerance researchers  ritter pharmaceuticals ritter pharmaceuticals  therapeutic treatments for gastrointestinal diseases careerscontact connect with us home about us history leadership overview leadership team medical advisory board board of directors lactose intolerance overview health consequences standard of care market opportunity patient resources microbiome modulation investors overview events  presentations corporate governance sec filings  stock info investor faqs contact us news press releases  news blog contact us contact us careers lactagen rpg product pipeline  print this page leadership we are committed to developing cuttingedge treatments for gastrointestinal diseases our management team with years of relevant clinical regulatory and commercial experience is supported by an outstanding medical advisory board comprised of foremost researchers in lactose intolerance and gastrointestinal diseases together we are committed to the vision of reducing the debilitating impact of lactose intolerance on patients globally leadership board of directors leadership team medical advisory board overview home    about us    investors    therapies    platform    leadership    lactose intolerance    news     contact us    privacy policy    terms  conditions    site map  copyright  ritter pharmaceuticals all rights reserved featuring recent posts wordpress widget development by yd ritter andrew j  the wall street transcript andrew j ritter andrew j ritter cofounder and president cofounded ritter pharmaceuticals inc nasdaqrttr upon his own personal affliction with lactose intolerance and spearheaded a global team of crossfunctional clinical manufacturing and regulatory experts to design and develop its first novel therapeutic called rpg the company was originally launched out of ritter naturals sciences a directtoconsumer health care marketing company founded by mr ritter in  which developed and commercialized digestive health care products lactagen health essentials and better digestion mr ritter holds six patents and over  additional international patents are pending he has copublished articles in nutrition journal gastroenterology and food technology and has given presentations at major health care and medical conferences such as digestive disease week among others since  mr ritter has also acted as managing partner of stonehenge partners a private investment fund which provides working capital and executive leadership to a variety of businesses and industries including real estate technology biotechnology entertainment and service businesses in addition he is a guest lecturer of entrepreneurship at various graduate and undergraduate academic institutions throughout los angeles including university of southern california marshall school of business university of california at los angeles anderson school of business and pepperdine university graziadio school of business and management mr ritter has been an active leader in his community including being appointed as a los angeles city commissioner to the commission for children youth and their families from  to  — the youngest appointed commissioner in los angeles history he holds a ba in political science and a minor in business from the university of southern california and was a member of the  pac champion baseball team mr ritter received his mba from the wharton school university of pennsylvania related interviewsinterview with the cofounder and president and the ceo ritter pharmaceuticals inc nasdaqrttrjuly   cartlatest newsall american usc footbal player joseph m boskovich jr now picks all american value stocks for his clientspaul hogan picks tech dividend growers microchip technology nasdaqmchp xilinx nasdaqxlnx and versum materials nysevsm gallons of water to produce a mcdonalds nysemcd quarter pounder how will investors profitthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsbuilding diversified portfolios with quality global equitiesgregory d padillaalberto jimenez crespo published july   in investing strategiescompanies covered amzn  aapl mu whr kimbera gs vod ppg shw viv pey buy building accountability and avoiding mistakes through the decision processdean pagonis published july   in investing strategiescompanies covered cmp sbh amzn ulta cvs lrlcy kmb www sdf buy finding optimal balance sheets by utilizing high yield market expertisezach miller published july   in investing strategiescompanies covered lsxmk siri bll chtr armk buy most popular reportsinvesting strategies published july  buy wireless communications  telecom published july  buy investing strategies published july  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsbuilding diversified portfolios with quality global equitiesbuilding accountability and avoiding mistakes through the decision processfinding optimal balance sheets by utilizing high yield market expertise analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google ritter pharmaceuticals reports fourth quarter and full year  financial results and provides business updatehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hrs  minssp  dow  nasdaq ritter pharmaceuticals reports fourth quarter and full year  financial results and provides business updatemarketwiredfebruary  reblogsharetweetsharelos angeles camarketwired  feb    ritter pharmaceuticals inc  nasdaq  rttr  ritter pharmaceuticals or the company a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases today reported financial results for the fourth quarter and full year ended december  recent highlightslast patient dosing and all monitoring visits of the companys phase b  subject clinical trial of lead product candidate rpg for the treatment of lactose intolerance was completed on schedule in october  initiated a month extension study to evaluate the longterm durability of rpg on a subset of phase b clinical trial patients in october  presented at the th microbiome rd business collaboration forum in october  raised gross proceeds of approximately  million in an underwritten public offering in october  to support operations and other general corporate purposes cnbc article published a race to turn trillions of our own bacterial into medical breakthroughs by andrew ritter was published in november  presented at the th annual ld micro main event in december  clinical microbiome data from the companys phase a clinical trial of rpg in patients with lactose intolerance was published in the proceedings of the national academy of science in january  appointed william merino phd to the companys board of directors in january  rang the closing bell at nasdaq in january  established a partnership with the university of nebraska and dr amanda ramertait to study the role of the microbiome and rpg in metabolic syndrome in january  and established a partnership with dr b brett finlay from the michael smith laboratories at the university of british columbia to study the role of the microbiome and rpg in environmental enteropathy was a significant year for ritter pharmaceuticals as we were able to successfully initiate and complete our phase b clinical trial in less than months hitting our target completion date and putting us in a position for anticipated data readout in the first quarter of  said michael d step chief executive officer of ritter pharmaceuticalsandrew j ritter president of ritter pharmaceuticals added this year we look forward to advancing rpg into phase  as we near one step closer to developing rpg as the first fda approved treatment for lactose intolerance while we also continue to look at expanding our product development efforts in additional indicationsfourth quarter and full year  financial resultsfor the fourth quarter of  ritter pharmaceuticals reported a net loss attributable to common stockholders of approximately  million compared to a net loss of approximately  million for the fourth quarter of  basic and diluted net loss per share was  for the three months ended december   compared to basic and diluted net loss per share of  for the same period in for the year ended december   ritter pharmaceuticals reported a net loss attributable to common stockholders of approximately  million compared to a net loss of approximately  million for the year ended december   basic and diluted net loss per share was approximately  for the year ended december   compared to basic and diluted net loss per share of approximately  for the same period in research and development expenses for the fourth quarter of  totaled approximately  million compared to approximately  for the fourth quarter of  this increase was due to the phase b clinical trialfor the year ended december   research and development expenses totaled approximately  million compared to approximately  million for the year ended december   the increase in research and development expenses was attributable to the phase b clinical study in general and administrative expenses for the fourth quarter of  were approximately  million compared to approximately  million for the fourth quarter of for the year ended december   general and administrative expenses were approximately  million compared to approximately  million for the year ended december   the decrease in general and administrative expenses was primarily due to lower stock based compensation expenses and continued cost containment measuresfor the year ended december   total operating expenses were  million compared to approximately  million for the year ended december  as of december   ritter pharmaceuticals had cash and cash equivalents of approximately  millionabout ritter pharmaceuticals ritter pharmaceuticals inc wwwritterpharmacom ritterpharma develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases its lead product rpg has the potential to become the first fdaapproved treatment for lactose intolerance a condition that affects millions worldwide the company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treatingpreventing a variety of conditions including gastrointestinal diseases immunooncology metabolic and liver diseaseforwardlooking statementsthis release may contain forwardlooking statements within the meaning of the private securities litigation reform act of  including statements related to our ability to bring rpg to market management believes that these forwardlooking statements are reasonable as and when made however such statements involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements these risks and uncertainties include but are not limited to risks associated with the drug development process generally including the outcomes of planned clinical trials and the regulatory review process for a discussion of certain risks and uncertainties affecting ritter pharmaceuticals forwardlooking statements please review the companys reports filed with the securities and exchange commission including but not limited to its annual report on form k for the year ended december   readers are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date on which they are made these statements are based on managements current expectations and ritter pharmaceuticals does not undertake any responsibility to revise or update any forwardlooking statements contained herein except as expressly required by law   ritter pharmaceuticals inc statements of operations       three months ended december      year ended  december                              unaudited         operating costs and expenses                                   research and development                           patent costs                               general and administrative                                 total operating costs and expenses                             operating loss                                                           other income                                   interest income                               other income                                 total other income                             net loss                                                       cumulative preferred stock dividends                            accretion of discount on series c preferred stock                            net loss applicable to common shareholders                                                       net loss per common share ― basic and diluted                                                       weightedaverage common shares outstanding  basic and diluted                                                                 ritter pharmaceuticals inc balance sheets     december       december                     assets               current assets                 cash and cash equivalents             prepaid expenses                 total current assets                             other assets             property and equipment net                 total assets                           liabilities and stockholders equity               current liabilities                 accounts payable             accrued expenses               other liabilities                 total current liabilities                             stockholders equity               preferred stock  par value  shares authorized no shares issued and outstanding             common stock  par value  shares authorized  and  shares issued and outstanding as of december   and december   respectively             additional paidin capital             accumulated deficit               total stockholders equity                                 total liabilities and stockholders equity           reblogsharetweetsharerecently viewedyour list is emptywhat to read nextverizon soars on beat starbucks big china deal astrazeneca sinks as drug trial disappointsyahoo financeengineer finds pattern makes millions in stocksmoney morningsponsoredshares in astrazeneca dive as key cancer drug trial failsassociated presspascal soriot here today after bad trial results wipe £bn from astrazeneca valuethe telegraphthe next aids pandemicforeign policy magazinetrunk club making sense of styletrunk clubsponsoredhas glioblastoma met its match in john mccaininternational business timestrump’s unwitting legacy could be universal health coverageyahoo financesean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insiderdiscover it  out of  avg by k customersdiscover cardsponsoredus economic growth picks up in second quarter wages continue to lagreuterstwitter is only famous now because of president trump nyse traderyahoo finance videoinvestors yawn as us economic growth rebounds in the second quarter amazon fallsyahoo financewomen need to carry this device with themsiren songsponsoredis a surprise coming for apple aapl this earnings seasonzackswall street opens lower as amazon weighs on tech stocksreutersus would utterly destroy north korea military says top army officialryan yes we could do what he said but not before north korea utterly destoryed seoul killing hundreds of thousands thats not even considering if they use a nukejoin the conversation   ritter pharmaceuticals reports first quarter  financial results and provides business updateshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hrs  minssp  dow  nasdaq ritter pharmaceuticals reports first quarter  financial results and provides business updatesmarketwiredmay  reblogsharetweetsharelos angeles camarketwired  may    ritter pharmaceuticals inc  nasdaq  rttr  ritter pharmaceuticals or the company a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases today reported financial results for the first quarter ended march   and provided other business updatesrecent highlightsclinical microbiome data from the companys phase a clinical trial of rpg in patients with lactose intolerance was published in the proceedings of the national academy of science appointed william merino phd to the companys board of directors rang the closing bell at nasdaq established a partnership with the university of nebraska and dr amanda ramertait to study the role of the microbiome and rpg in metabolic syndrome established a partnership with dr b brett finlay from the michael smith laboratories at the university of british columbia to study the role of the microbiome and rpg in environmental enteropathy announced topline data from our phase b clinical trial of rpg in patients with lactose intolerance announced the issuance of three new patents two in the us and one in australia directed toward compositions containing and methods of using rpg and established a new equity facility with aspire capital fund llc on may   to give the company the flexibility and capability to access up to  million in equity capital in the future at the companys sole discretion the key event of the quarter was our announcement of topline data from our phase b clinical trial of rpg in patients with lactose intolerance results from the trial demonstrated a clinically meaningful benefit in subjects with the reduction of lactose intolerance symptoms we are now looking forward to commencing our phase  program following our endofphase  meeting with the fda to discuss the steps needed for an nda submission said michael d step chief executive officer of ritter pharmaceuticalsandrew j ritter cofounder and president of ritter pharmaceuticals added we look forward to advancing rpg into phase  taking us one step closer to developing the first fdaapproved treatment for lactose intolerance a condition suffered by over  million in the us and millions more worldwidefirst quarter  financial resultsfor the first quarter of  ritter pharmaceuticals reported a net loss attributable to common stockholders of approximately  million compared to a net loss of approximately  million for the first quarter of  basic and diluted net loss per share was  for the three months ended march   compared to basic and diluted net loss per share of  for the same period in research and development expenses for the first quarter of  totaled approximately  compared to approximately  million for the first quarter of  this decrease was due to the completion of the phase b clinical trialgeneral and administrative expenses for the first quarter of  and  were approximately  millionas of march   ritter pharmaceuticals had cash and cash equivalents of approximately  millionabout ritter pharmaceuticals ritter pharmaceuticals inc wwwritterpharmacom ritterpharma develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases its lead product candidate rpg has the potential to become the first fdaapproved treatment for lactose intolerance a condition that affects millions worldwide the company is further exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treatingpreventing a variety of conditions including gastrointestinal diseases immunooncology metabolic and liver diseaseforwardlooking statementsthis release may contain forwardlooking statements within the meaning of the private securities litigation reform act of  including statements related to our ability to bring rpg to market management believes that these forwardlooking statements are reasonable as and when made however such statements involve a number of known and unknown risks and uncertainties that could cause the companys future results performance or achievements to differ significantly from the results performance or achievements expressed or implied by such forwardlooking statements these risks and uncertainties include but are not limited to risks associated with the drug development process generally including the outcomes of planned clinical trials and the regulatory review process for a discussion of certain risks and uncertainties affecting ritter pharmaceuticals forwardlooking statements please review the companys reports filed with the securities and exchange commission including but not limited to its annual report on form k for the year ended december   readers are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date on which they are made these statements are based on managements current expectations and ritter pharmaceuticals does not undertake any responsibility to revise or update any forwardlooking statements contained herein except as expressly required by law     ritter pharmaceuticals inc   condensed statements of operations   unaudited           for the three months ended march                operating costs and expenses                   research and development               patent costs                 general and administrative                   total operating costs and expenses                                 operating loss                               other income                   interest income                 other income                   total other income                                         net loss                                               net loss per share basic and diluted                             weighted average shares outstanding basic and diluted                                                                     ritter pharmaceuticals inc   condensed balance sheets           march       december         unaudited         assets                 current assets                   cash and cash equivalents               prepaid expenses                   total current assets                                 other assets               property and equipment net                   total assets                               liabilities and stockholders equity                 current liabilities                   accounts payable               accrued expenses                 other liabilities                   total current liabilities                                 stockholders equity                 preferred stock  par value  shares authorized  shares issued and outstanding as of march   and december                 common stock  par value  shares authorized  shares issued and outstanding as of march   and december                 additional paidin capital               accumulated deficit                 total stockholders equity                                     total liabilities and stockholders equity             reblogsharetweetsharerecently viewedyour list is emptywhat to read nextverizon soars on beat starbucks big china deal astrazeneca sinks as drug trial disappointsyahoo financeengineer finds pattern makes millions in stocksmoney morningsponsoredfj companys fj is the toyota land cruiser you really wantautoblogshares in astrazeneca dive as key cancer drug trial failsassociated pressjeff bezos’ brief stint as world’s richest human ends with amazon’s secondquarter whifftechcrunchdiscover it  out of  avg by k customersdiscover cardsponsoredpascal soriot here today after bad trial results wipe £bn from astrazeneca valuethe telegraphtrump’s unwitting legacy could be universal health coverageyahoo financesean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insiderwomen need to carry this device with themsiren songsponsoredus economic growth picks up in second quarter wages continue to lagreuterstwitter is only famous now because of president trump nyse traderyahoo finance videoinvestors yawn as us economic growth rebounds in the second quarter amazon fallsyahoo financezuckerberg wifes ambitious secret finally exposedunewzmesponsoredis a surprise coming for apple aapl this earnings seasonzackswall street opens lower as amazon weighs on tech stocksreutersus would utterly destroy north korea military says top army officialryan yes we could do what he said but not before north korea utterly destoryed seoul killing hundreds of thousands thats not even considering if they use a nukejoin the conversation